atopic dermatitis

[VYNE Therapeutics Inc.] VYNE Therapeutics Inc. announced positive efficacy results from the Phase Ib segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis.

[Frontiers in Bioengineering and Biotechnology] Investigators summarize the key features of psoriasis and atopic dermatitis, the different types of in vitro models available to study their pathophysiology and evaluate their efficacy in addition to discussing future research opportunities.

[International Journal of Stem Cells] Scientists investigated the immunomodulatory effect of epidermal growth factor (EGF) secreted by hUCB-MSCs on atopic dermatitis.

[Evelo Biosciences, Inc.] Evelo Biosciences, Inc. announced data from the post-treatment follow-up of its Phase II trial of EDP1815 in mild and moderate psoriasis including durable and deeper clinical responses.

[Science Translational Medicine] Investigators examined human atopic dermatitis (AD) skin samples and found that human AD fibroblasts also overexpressed C-C motif chemokine ligand 11 (CCL11) and that perturbation of Ikkb–NF-κB in primary human dermal fibroblasts up-regulated CCL11.

[Journal of Investigative Dermatology] Researchers stimulated post-confluent human keratinocytes and living skin equivalent with TSLP to investigate the role of nuclear IL-33 in TSLP-induced epidermal barrier defects.